

Learner Notification

Kneed Communications

Bethesda - Advancing the Diagnostic-to-Treatment Continuum in Cancer Care

July 17, 2026

Bethesda, MD

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163

Physicians

Amedco LLC designates this live activity for a maximum of 6.50 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 6.50 knowledge-based CPE contact hours.

UAN JA4008163-9999-26-193-L01-P

NOTE to Pharmacists: *The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.*

Nurses

Amedco LLC designates this activity for a maximum of 6.50 ANCC contact hours.

American Board of Pathology (ABPath) MOC

This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 6.50 credit hours.

You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Identify emerging translational and clinical advances in biomarker-driven solid tumors, including RAS-, CLDN18.2-, BRAF-, and MTAP-altered cancers, to support improved patient selection and treatment planning.
2. Apply biomarker-informed and multidisciplinary strategies to evaluate targeted and combination treatment approaches for patients with gastrointestinal and other solid tumor malignancies.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Nilo Azad	AstraZeneca, Revolution Medicine, Beigene, Atlas, Mirati/BMS, Incyte, Taiho, Syndax, Bayer, Pfizer/Seagen, Compass :Research Grant Overall Principal Investigator Agenus, GlaxoSmithKline, AstraZeneca, Revolution Medicine, Astellas, Eli Lilly, Tempus, Beigene, Incyte :Consultant Haystack Oncology/Quest, Cage Pharma, Irazu:Private Stock Shareholder
Jonathan Brody	Perthera , PanCAN:Scientific/Medical Advisory Board Member Faster Better Media, LLC:Owner Oregon Health & Science University:Research Grant Site Principal Investigator Taylor and Francis, NIH, Dept of Defense:Other Rimon Law:Consultant
Andrea Cercek	Amgen, Abbvie, Agenus, Daiichi-Saynko, Merck, GSK, Pfizer, Roche, Janssen, Summit, 3T Biosciences, Urogen and Regeneron:Scientific/Medical Advisory Board Member GSK, Pfizer:Research Grant Overall Principal Investigator
Eric Christenson	Boston Scientific, Parabilis:Scientific/Medical Advisory Board Member SirTex, Urogen Therapeutics, Pfizer:Consultant Haystack Oncology/Quest, Regeneron, Agenus:Research Grant Overall Principal Investigator Affimed GMBH, NextCure, Incyte, Parabilis:Research Grant Site Principal Investigator
Jennifer Hanle	Pfizer, Sanofi:Speakers Bureau
Valerie Lee	Incyte:Scientific/Medical Advisory Board Member
Howard McLeod	NA
Sandra Misale	Merck:Consultant AstraZeneca:Research Grant Site Principal Investigator Thera65 Srl:Scientific/Medical Advisory Board Member
Kathleen Mulvaney	NA
Haeseong Park	Exelixis, Tizona, Bolt Biotherapeutics, Chugai, Huaota, D3Bio, Amgen, Idience, Incyte, Pfizer, Alterome, Yuhan, Genentech, MediLink, Dewpoint:Research Grant Site Principal Investigator
Emanuel Petricoin	Ignite Proteomics, LLC., Perthera, Inc., Ceres Nanosciences, Inc., DAIANA, Targeted Biosciences:Consultant
Mike Pishvaian	Astra Zeneca, Merus, Merck, Moderna, Novartis, Astellas, Serna Bio, Revolution Medicines, Novocure:Consultant Astellas, RenovoRx, Sanofi:Scientific/Medical Advisory Board Member Merus, Novocure, Revolutions Medicines:Other

	Revolution Medicines, Tesaro, Arcus Bio, Ideaya, Repare Tx, Novartis, Pfizer, Merck, Amgen, RenovoRx, Boehringer Ingelheim, Astellas, Takeda, Actuate, MEI Pharma, Elevation Oncology, Recursion Pharma, Eli Lilly, Parabalis:Research Grant Site Principal Investigator
Deanna Russell	NA
Nigel Russell	NA
Nima Sharifai	NA
Matthew Strickland	BMS, Astellas, Bayer, UpToDate:Consultant
	Bristol-Myers Squibb, Merck, Abbvie, and Astrazeneca, Merck, AbbVie:Research Grant Overall Principal Investigator
Lei Zheng	Biosion, Amberstone, Tallac, Fortress, Pfizer:Consultant Amberstone, Alphamab:Public Stock Shareholder Cellaration , LYK Consulting :Owner
Naomi Terlouw	NA

How to Get Your Certificate

1. Go to kc.cmecertificateonline.com
2. Click on the **2026 Bethesda - Advancing the Diagnostic-to-Treatment Continuum in Cancer Care** link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com